Outlook Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| OTLK | ONCY | TRDA | OSTX | PTX.AX | ACTI.ST | |
|---|---|---|---|---|---|---|
| Market cap | 112.50M | 55.70M | 197.02M | 53.83M | 60.62M | 101.09M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.9 | -2.1 | -1.6 | 3.3 | 5.3 | — |
| Price/book | -8.3 | -8.7 | 0.8 | -4.4 | 3.8 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −63.20% | −58.42% | −27.19% | −35.56% | +10.87% | −42.74% |
| Today | +0.46% | +8.92% | +7.20% | −0.86% | +3.92% | +4.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All OTLK news ›Outlook Therapeutics Names Greg DiPasquale as CCO | VM
ISELIN, N.J.—Outlook Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of Lytenava (bevacizumab-vikg) for the treatment of retinal diseases, announced Greg DiPasquale has been appointed CCO.…
More from 1 other outlet
Outlook Therapeutics: Empery reports 8.73% stake
Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). Stock Titan - [SCHEDULE 13G] Outlook Therapeutics, Inc. Passive Investment Disclosure (>5%) Outlook Therapeutics: Empery reports 8.73% stake The…
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer as OTLK Prepares Lytenava Launch
The GF Score™ aggregates multiple facets of a company’s financial health, including profitability, growth, financial strength, valuation, and momentum, to provide a holistic snapshot of its investment quality. Outlook Therapeutics’ GF…
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
October 06, 2026 09:20 ET | Source: Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- globenewswire.com1
- gurufocus.com1
- manilatimes.net1
- mobile.visionmonday.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.